Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Adult plant resistance in maize to northern leaf spot is a feature of partial loss-of-function alleles of Hm1.

Marla SR, Chu K, Chintamanani S, Multani DS, Klempien A, DeLeon A, Bong-Suk K, Dunkle LD, Dilkes BP, Johal GS.

PLoS Pathog. 2018 Oct 17;14(10):e1007356. doi: 10.1371/journal.ppat.1007356. eCollection 2018 Oct.

2.

Safety and Immunogenicity of a Recombinant Influenza Vaccine: A Randomized Trial.

Dunkle LM, Izikson R, Patriarca PA, Goldenthal KL, Cox M, Treanor JJ.

Pediatrics. 2018 May;141(5). pii: e20173021. doi: 10.1542/peds.2017-3021. Epub 2018 Apr 2.

PMID:
29610401
3.

Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18-49 Years of Age.

Dunkle LM, Izikson R, Patriarca PA, Goldenthal KL, Muse D, Cox MMJ.

J Infect Dis. 2017 Dec 5;216(10):1219-1226. doi: 10.1093/infdis/jix478.

PMID:
28968871
4.

Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older.

Dunkle LM, Izikson R, Patriarca P, Goldenthal KL, Muse D, Callahan J, Cox MMJ; PSC12 Study Team.

N Engl J Med. 2017 Jun 22;376(25):2427-2436. doi: 10.1056/NEJMoa1608862.

5.

Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial.

Treanor JJ, Chu L, Essink B, Muse D, El Sahly HM, Izikson R, Goldenthal KL, Patriarca P, Dunkle LM.

Vaccine. 2017 Feb 7;35(6):923-928. doi: 10.1016/j.vaccine.2016.12.053. Epub 2017 Jan 11.

PMID:
28089141
6.

Recombinant hemagglutinin influenza vaccine provides broader spectrum protection.

Dunkle LM, Izikson R.

Expert Rev Vaccines. 2016 Aug;15(8):957-66. doi: 10.1080/14760584.2016.1203261. Epub 2016 Jul 4. Review.

PMID:
27314982
7.

Randomized comparison of the safety of Flublok(®) versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥ 50 years of age.

Izikson R, Leffell DJ, Bock SA, Patriarca PA, Post P, Dunkle LM, Cox MM.

Vaccine. 2015 Nov 27;33(48):6622-8. doi: 10.1016/j.vaccine.2015.10.097. Epub 2015 Nov 1.

PMID:
26529070
8.

Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults.

Cox MM, Izikson R, Post P, Dunkle L.

Ther Adv Vaccines. 2015 Jul;3(4):97-108. doi: 10.1177/2051013615595595. Review.

9.

Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant.

Treanor JJ, Essink B, Hull S, Reed S, Izikson R, Patriarca P, Goldenthal KL, Kohberger R, Dunkle LM.

Vaccine. 2013 Nov 19;31(48):5760-5. doi: 10.1016/j.vaccine.2013.08.064. Epub 2013 Sep 27.

PMID:
24075920
10.

Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials.

Caseiro MM, Nelson M, Diaz RS, Gathe J, de Andrade Neto JL, Slim J, Solano A, Netto EM, Mak C, Shen J, Greaves W, Dunkle LM, Vilchez RA, Zeinecker J.

J Infect. 2012 Oct;65(4):326-35. doi: 10.1016/j.jinf.2012.05.008. Epub 2012 May 24.

PMID:
22634184
11.

Regulation of stomatal tropism and infection by light in Cercospora zeae-maydis: evidence for coordinated host/pathogen responses to photoperiod?

Kim H, Ridenour JB, Dunkle LD, Bluhm BH.

PLoS Pathog. 2011 Jul;7(7):e1002113. doi: 10.1371/journal.ppat.1002113. Epub 2011 Jul 28.

12.

A circadian rhythm regulating hyphal melanization in Cercospora kikuchii.

Bluhm BH, Burnham AM, Dunkle LD.

Mycologia. 2010 Nov-Dec;102(6):1221-8. doi: 10.3852/09-041. Epub 2010 Jul 13.

PMID:
20943572
13.

Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5.

Ogert RA, Hou Y, Ba L, Wojcik L, Qiu P, Murgolo N, Duca J, Dunkle LM, Ralston R, Howe JA.

Virology. 2010 Apr 25;400(1):145-55. doi: 10.1016/j.virol.2010.01.037. Epub 2010 Feb 21.

14.

Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial.

Suleiman J, Zingman BS, Diaz RS, Madruga JV, DeJesus E, Slim J, Mak C, Lee E, McCarthy MC, Dunkle LM, Walmsley S.

J Infect Dis. 2010 Feb 15;201(4):590-9. doi: 10.1086/650342.

PMID:
20064072
15.

Permanent Genetic Resources added to Molecular Ecology Resources database 1 January 2009-30 April 2009.

Molecular Ecology Resources Primer Development Consortium, Abercrombie LG, Anderson CM, Baldwin BG, Bang IC, Beldade R, Bernardi G, Boubou A, Branca A, Bretagnolle F, Bruford MW, Buonamici A, Burnett RK Jr, Canal D, Cárdenas H, Caullet C, Chen SY, Chun YJ, Cossu C, Crane CF, Cros-Arteil S, Cudney-Bueno R, Danti R, Dávila JA, Della Rocca G, Dobata S, Dunkle LD, Dupas S, Faure N, Ferrero ME, Fumanal B, Gigot G, González I, Goodwin SB, Groth D, Hardesty BD, Hasegawa E, Hoffman EA, Hou ML, Jamsari AF, Ji HJ, Johnson DH, Joseph L, Justy F, Kang EJ, Kaufmann B, Kim KS, Kim WJ, Koehler AV, Laitung B, Latch P, Liu YD, Manjerovic MB, Martel E, Metcalfe SS, Miller JN, Midgley JJ, Migeon A, Moore AJ, Moore WL, Morris VR, Navajas M, Navia D, Neel MC, De Nova PJ, Olivieri I, Omura T, Othman AS, Oudot-Canaff J, Panthee DR, Parkinson CL, Patimah I, Pérez-Galindo CA, Pettengill JB, Pfautsch S, Piola F, Potti J, Poulin R, Raimondi PT, Rinehart TA, Ruzainah A, Sarver SK, Scheffler BE, Schneider AR, Silvain JF, Siti Azizah MN, Springer YP, Stewart CN, Sun W, Tiedemann R, Tsuji K, Trigiano RN, Vendramin GG, Wadl PA, Wang L, Wang X, Watanabe K, Waterman JM, Weisser WW, Westcott DA, Wiesner KR, Xu XF, Yaegashi S, Yuan JS.

Mol Ecol Resour. 2009 Sep;9(5):1375-9. doi: 10.1111/j.1755-0998.2009.02746.x. Epub 2009 Jul 17.

PMID:
21564911
16.

Analyses of expressed sequence tags from the maize foliar pathogen Cercospora zeae-maydis identify novel genes expressed during vegetative, infectious, and reproductive growth.

Bluhm BH, Dhillon B, Lindquist EA, Kema GH, Goodwin SB, Dunkle LD.

BMC Genomics. 2008 Nov 4;9:523. doi: 10.1186/1471-2164-9-523.

17.

Sibling species of cercospora associated with gray leaf spot of maize.

Wang J, Levy M, Dunkle LD.

Phytopathology. 1998 Dec;88(12):1269-75. doi: 10.1094/PHYTO.1998.88.12.1269.

18.

Genetic Relatedness of African and United States Populations of Cercospora zeae-maydis.

Dunkle LD, Levy M.

Phytopathology. 2000 May;90(5):486-90. doi: 10.1094/PHYTO.2000.90.5.486.

19.

Microcycle Conidiation in Cercospora zeae-maydis.

Lapaire CL, Dunkle LD.

Phytopathology. 2003 Feb;93(2):193-9. doi: 10.1094/PHYTO.2003.93.2.193.

20.

Phylogenetic analysis of cercospora and mycosphaerella based on the internal transcribed spacer region of ribosomal DNA.

Goodwin SB, Dunkle LD, Zismann VL.

Phytopathology. 2001 Jul;91(7):648-58. doi: 10.1094/PHYTO.2001.91.7.648.

21.

PHL1 of Cercospora zeae-maydis encodes a member of the photolyase/cryptochrome family involved in UV protection and fungal development.

Bluhm BH, Dunkle LD.

Fungal Genet Biol. 2008 Oct;45(10):1364-72. doi: 10.1016/j.fgb.2008.07.005. Epub 2008 Jul 19.

PMID:
18682297
22.

RAS2 regulates growth and pathogenesis in Fusarium graminearum.

Bluhm BH, Zhao X, Flaherty JE, Xu JR, Dunkle LD.

Mol Plant Microbe Interact. 2007 Jun;20(6):627-36.

23.

Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults.

Schürmann D, Fätkenheuer G, Reynes J, Michelet C, Raffi F, van Lier J, Caceres M, Keung A, Sansone-Parsons A, Dunkle LM, Hoffmann C.

AIDS. 2007 Jun 19;21(10):1293-9.

PMID:
17545705
24.

Fine mapping of the Pc locus of Sorghum bicolor, a gene controlling the reaction to a fungal pathogen and its host-selective toxin.

Nagy ED, Lee TC, Ramakrishna W, Xu Z, Klein PE, SanMiguel P, Cheng CP, Li J, Devos KM, Schertz K, Dunkle L, Bennetzen JL.

Theor Appl Genet. 2007 Apr;114(6):961-70. Epub 2007 Mar 14.

PMID:
17356869
25.

Malazy, a degenerate, species-specific transposable element in Cercospora zeae-maydis.

Shim WB, Dunkle LD.

Mycologia. 2005 Mar-Apr;97(2):349-55.

PMID:
16396343
26.
28.

A Rapid PCR-Based Method for the Detection of Magnaporthe oryzae from Infected Perennial Ryegrass.

Harmon PF, Dunkle LD, Latin R.

Plant Dis. 2003 Sep;87(9):1072-1076. doi: 10.1094/PDIS.2003.87.9.1072.

PMID:
30812820
29.

Host-selective toxins and avirulence determinants: what's in a name?

Wolpert TJ, Dunkle LD, Ciuffetti LM.

Annu Rev Phytopathol. 2002;40:251-85. Epub 2002 Feb 20. Review.

PMID:
12147761
30.

Differential synthesis of peritoxins and precursors by pathogenic strains of the fungus Periconia circinata.

Churchill AC, Dunkle LD, Silbert W, Kennedy KJ, Macko V.

Appl Environ Microbiol. 2001 Dec;67(12):5721-8.

31.

Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals.

Raboud JM, Montaner JS, Rae S, Kahn J, Hammer SM, Katzenstein DA, Pavia A, Dolin R, Hughes MD, Cross A, Beltangady M, Gatell J, Dunkle L, Smaldone L.

Antivir Ther. 1997 Dec;2(4):237-47.

PMID:
11327443
32.
33.

The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.

Elion R, Kaul S, Knupp C, Adler M, Cross AP, Dunkle LM, Kelleher T.

Clin Ther. 1999 Nov;21(11):1853-63.

PMID:
10890257
34.

Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3.

Pollard RB, Peterson D, Hardy D, Pottage J, Murphy RL, Gathe J, Beall G, Rutkievicz V, Reynolds L, Cross AP, Dunkle LM.

J Acquir Immune Defic Syndr. 1999 Sep 1;22(1):39-48.

PMID:
10534145
35.
36.

A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults.

Haworth SJ, Christofalo B, Anderson RD, Dunkle LM.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Mar 1;17(3):235-8.

PMID:
9495223
37.
38.

Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group.

Spruance SL, Pavia AT, Mellors JW, Murphy R, Gathe J Jr, Stool E, Jemsek JG, Dellamonica P, Cross A, Dunkle L.

Ann Intern Med. 1997 Mar 1;126(5):355-63.

PMID:
9054279
39.

Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects.

Kline MW, Fletcher CV, Federici ME, Harris AT, Evans KD, Rutkiewicz VL, Shearer WT, Dunkle LM.

Pediatrics. 1996 Jun;97(6 Pt 1):886-90.

PMID:
8657531
40.

Morphogenic Regulation of Pathotoxin Synthesis in Cochliobolus carbonum

Weiergang I I, Dunkle LD, Wood KV, Nicholson RL.

Fungal Genet Biol. 1996 Mar;20(1):74-8.

PMID:
8812288
41.

Stavudine (d4T, Zerit).

Friedland G, Dunkle LW, Cross AP.

Adv Exp Med Biol. 1996;394:271-7. Review. No abstract available.

PMID:
8815691
42.

Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group.

Montaner JS, Schechter MT, Rachlis A, Gill J, Beaulieu R, Tsoukas C, Raboud J, Cameron B, Salomon H, Dunkle L, Smaldone L, Wainberg MA.

Ann Intern Med. 1995 Oct 15;123(8):561-71.

PMID:
7677296
43.

Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex.

Horton CM, Dudley MN, Kaul S, Mayer KH, Squires K, Dunkle L, Anderson R.

Antimicrob Agents Chemother. 1995 Oct;39(10):2309-15.

44.

A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection.

Kline MW, Dunkle LM, Church JA, Goldsmith JC, Harris AT, Federici ME, Schultze ME, Woods L, Loewen DF, Kaul S, et al.

Pediatrics. 1995 Aug;96(2 Pt 1):247-52.

PMID:
7630678
45.

Long-term survivors of human immunodeficiency virus type 1 infection.

Dunkle LM.

N Engl J Med. 1995 Jun 15;332(24):1647; author reply 1647-8. No abstract available.

PMID:
7753147
46.

Virulence gene expression during conidial germination in Cochliobolus carbonum.

Jones MJ, Dunkle LD.

Mol Plant Microbe Interact. 1995 May-Jun;8(3):476-9.

PMID:
7655067
47.

Dose-related activity of stavudine in patients infected with human immunodeficiency virus.

Petersen EA, Ramírez-Ronda CH, Hardy WD, Schwartz R, Sacks HS, Follansbee S, Peterson DM, Cross A, Anderson RE, Dunkle LM.

J Infect Dis. 1995 Mar;171 Suppl 2:S131-9.

PMID:
7861018
48.

Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089.

Murray HW, Squires KE, Weiss W, Sledz S, Sacks HS, Hassett J, Cross A, Anderson RE, Dunkle LM.

J Infect Dis. 1995 Mar;171 Suppl 2:S123-30.

PMID:
7861017
49.

Design and implementation of the stavudine parallel-track program.

Anderson RE, Dunkle LM, Smaldone L, Adler M, Wirtz C, Kriesel D, Cross A, Martin RR.

J Infect Dis. 1995 Mar;171 Suppl 2:S118-22.

PMID:
7861016
50.

Analysis of potential risk factors associated with the development of pancreatitis in phase I patients with AIDS or AIDS-related complex receiving didanosine.

Grasela TH, Walawander CA, Beltangady M, Knupp CA, Martin RR, Dunkle LM, Barbhaiya RH, Pittman KA, Dolin R, Valentine FT, et al.

J Infect Dis. 1994 Jun;169(6):1250-5.

PMID:
8195601

Supplemental Content

Loading ...
Support Center